Revance Therapeutics’ $17 Million Investor Settlement Receives Preliminary Approval
On Tuesday, April 14, 2026, a federal judge granted preliminary approval to a $17 million settlement resolving a class-action securities lawsuit against Revance Therapeutics, Inc. (NASDAQ: RVNC). The lawsuit alleged that Revance misled investors regarding the FDA approval process for its lead drug candidate, DaxibotulinumtoxinA (DAXI) for injection. Specifically, the suit claimed the company failed…
